相关临床试验
39
10 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1996
进行中（未招募）
8
20.5%
已完成
11
28.2%
尚未招募
2
5.1%
招募中
6
15.4%
暂停
1
2.6%
终止
8
20.5%
Unknown
2
5.1%
撤回
1
2.6%
暂无批准数据
- NDSU and Sanford Health are launching a study to assess real-world impacts of GLP-1 medications on quality of life, emotional state, and muscle wasting. - The study will follow participants at treatment start, three months, and six months, with enrollment expected to open in late July. - Researchers note early literature hints GLP-1s may be protective against substance use issues, unlike bariatric surgery where 1 in 5 patients develop such problems. - An estimated 1 in 8 Americans now take a GLP-1 drug, yet long-term outcomes and complications remain poorly understood.
- Chrystal Moldenhauer, diagnosed with cystic fibrosis (CF) at three months old, has experienced a significant improvement in her quality of life due to advances in medicine and comprehensive care at Sanford Health. - Effective medications, including Kalydeco, have reduced the need for extensive daily treatments, allowing Chrystal to engage more fully in family life and other activities. - The median age at death for people with CF was 66 years in 2022, and their life expectancy was only 12% lower than that of healthy people. - Chrystal's care team emphasizes the importance of patient diligence and participation in drug trials for the continued development of new and improved CF treatments.
- The EVOLVE clinical trial at Sanford Health investigates reduced-intensity treatment for throat cancer, aiming to lessen side effects. - The trial protocol uses a lower radiation dose delivered in 20 fractions over 10 days, compared to the standard 30 fractions over six weeks. - Preliminary results indicate that the reduced radiation schedule maintains efficacy while decreasing common side effects like swallowing difficulties and dry mouth. - One patient's experience highlights the trial's success, showing cancer remission and a return to normal activities post-treatment.
